Imprimis Pharmaceuticals, Inc.
12264 El Camino Real
About Imprimis Pharmaceuticals, Inc.
147 articles with Imprimis Pharmaceuticals, Inc.
Companies are taking a look at providing compounded versions of drugs. However, last week, new guidelines put forth by the U.S. FDA would hinder the notion of compounded drugs being sold due to price increases. The new guidelines will address the limits of compounded drugs that can be shipped acr...
Imprimis Pharmaceuticals, Inc. reported results for the second quarter 2018.
Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in Canada
Study to assess drug safety, patient preference and pharmacoeconomic measures in 200 routine cataract surgeries
Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018
Imprimis Pharmaceuticals, Inc. announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9th, 2018 at 11:00 a.m. ET in the London Room at the InterContinental Boston Hotel in Boston, MA.
ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery
Imprimis Pharmaceuticals, Inc.'s is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018.
Investment will enable Surface to fund its development programs focused on FDA approval of its ocular disease drug candidates
New combination topical drops and other cGMP (current good manufacturing practices) formulations will be showcased
Non-opioid IV-free procedural sedation and pain relief could aid in the battle against opioid abuse.
Imprimis Pharmaceuticals secured a patent that protects its non-opioid sublingual product MKO Melt compound formulation and investors are pleased.
Imprimis Pharmaceuticals, Inc. reported financial results for the fourth quarter 2017.
Company dedicated to meeting the need for critical, hard-to-find medications with ease of access
Imprimis Pharma to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST
The company will host a conference call at 4:30 p.m. EST/1:30 p.m. PST on the same day to discuss the financial results and recent business developments.
Imprimis today announced that it is now dispensing preservative-free dorzolamide and a preservative-free dorzolamide/timolol formulation after dorzolamide and the commercial products, Cosopt and Cosopt PF, were added to the FDA Drug Shortage List.
This new registration will further allow Imprimis to leverage its national compounding platform and its relationships with nearly 2,000 ophthalmology and optometric customers.
The Dec. 21 letter to San Diego-based Imprimis was posted on the FDA’s website on Tuesday.
Gross ophthalmology-related revenue of $4.9M, up over 60% year-over-year.
Imprimis Pharma to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST
Imprimis today announced it will release third quarter 2017 financial results after the close of trading on Tuesday, November 14, 2017.
Imprimis Pharma today announced it has filed a Form 8-K with the SEC which contains a corporate presentation for its subsidiary, Surface Pharma.
Imprimis today announced it is making compounded Cyclosporine-based formulations available for physicians to consider prescribing as customizable and potentially lower-cost alternatives to Restasis.